Stocks
Immuron LimitedIMRN
NASDAQHealthcareBiotechnology$0.95
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral immunotherapies for chronic inflammatory and infectious diseases. Its lead programs target the gut mucosa to treat conditions like ulcerative colitis and recurrent C. difficile infections. Investors track Immuron for its novel platform and potential to address large gastrointestinal markets.
52W Range: $0.68-$2.24
Congressional Interest in Immuron Limited (IMRN)
No congressional trades have been disclosed for Immuron Limited (IMRN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IMRN?
No congressional trades found for this stock.